This may save your life cancer?

"Interim study results show prolonged survival for Pfizer's axitinib in advanced pancreatic cancer.

While final results need to be corroborated in an upcoming Phase III study, Pfizer's axitinib shows early potential to fulfill the great unmet need associated with pancreatic cancer. Given that OSI Pharmaceuticals/Genentech/Roche's Tarceva was granted FDA approval in this indication based on a two-week survival benefit, it is likely positive results would be met with great enthusiasm."